ACHV

Achieve Life Sciences, Inc. (ACHV) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline for smoking and vaping cessation. The company has no approved products and has not generated product revenue to date. As of May 12, 2026, there were 102,659,057 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is $0 as the company has no commercial products. Cash balance includes $28,078 in cash equivalents and $1,191 in marketable securities.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $2.7 million (21%) compared to Q1 2025, driven primarily by a reduction in Research and Development (R&D) expenses.
• R&D Expenses: Decreased to $3.3 million from $7.1 million. This was due to the wind-down of the ORCA-OL clinical trial (completed in September 2025) and a $1.0 million decrease in stock-based compensation due to revaluation of performance-based restricted stock units (PRSUs).
• G&A Expenses: Increased to $7.2 million from $5.8 million. The increase was driven by $3.2 million in commercial launch preparation costs, higher employee expenses, and increased legal fees, partially offset by a decrease in stock-based compensation.
• Stock-Based Compensation: The company recorded a net reversal of $0.7 million in stock-based compensation expense for Q1 2026, compared to an expense of $2.2 million in Q1 2025.
• Contingent Consideration: Recognized a gain of $0.3 million related to the fair value adjustment of contingent consideration owed to Sopharma AD, compared to a loss of $0.1 million in the prior year.

Guidance, Outlook, and Risks

• Regulatory Status: The FDA accepted the New Drug Application (NDA) for cytisinicline for smoking cessation in September 2025, with a PDUFA target action date of June 20, 2026. However, the company expects to receive a Complete Response Letter (CRL) due to FDA observations at a third-party manufacturer's facility (Official Action Indicated classification). The company plans to resubmit the NDA in Q4 2026 with a new U.S.-based manufacturer (Adare Pharma Solutions) and anticipates a commercial launch in the first half of 2027.
• Subsequent Financing: In April 2026, the company completed a private placement raising approximately $180.0 million in gross proceeds (estimated net proceeds of $168.6 million). This significantly improves liquidity.
• Leadership Change: Effective April 18, 2026, Andrew D. Goldberg, M.D., was appointed as Chief Executive Officer and President.
• Key Risks:
  • Regulatory Delay: Anticipated CRL and need for NDA resubmission.
  • Manufacturing Dispute: Ongoing dispute with Sopharma AD regarding the engagement of third-party manufacturers.
  • Debt Obligations: $15.0 million in convertible debt with SVB, interest-only until June 2026, maturing in 2028.
  • Supply Chain: Reliance on third-party manufacturers and natural plant sources for cytisinicline.

Investor Verification Checklist

• Verify the status of the FDA inspection at the third-party manufacturer and the timeline for the NDA resubmission.
• Confirm the resolution status of the legal dispute with Sopharma AD regarding manufacturing rights.
• Review the terms of the April 2026 private placement, specifically the exercise prices of warrants and pre-funded warrants issued.
• Assess the impact of the new CEO appointment on strategic execution and commercial launch readiness.
• Monitor the company's cash burn rate post-financing to ensure sufficiency for the anticipated 2027 launch.